New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, CT 06030, USA.
Bone. 2013 Jul;55(1):248-55. doi: 10.1016/j.bone.2013.02.010. Epub 2013 Feb 26.
Cathepsin K inhibitors (CatK-I) have been developed and established to restore bone mass in both animal models of bone loss and postmenopausal osteoporotic patients. We investigated the effects of a CatK-I L-006235 on bone repair and compared to alendronate (ALN) for its known effects on fracture healing in preclinical models. Femoral fractures were performed on wild type mice that were given vehicle (CON), CatK-I or ALN from day 0 post-fracture until euthanasia. Radiologic and micro-CT analyses demonstrated that CatK-I enhanced mineralization within the calluses at day 21 post-fracture, but to a lesser degree than ALN. Histological analyses showed residual unmineralized and mineralized cartilage in the calluses of CatK-I and ALN treated groups at day 21 post-fracture compared to that in CON. CatK-I enhanced the number of tartrate-resistant acid phosphatase positive (TRAP+) osteoclasts in the fracture calluses compared to ALN and CON treated groups. However, relative levels of serum C-terminal telopeptides of type I collagen (CTX) normalized to the number of TRAP+ osteoclasts within the calluses were significantly decreased in both CatK-I and ALN groups compared to CON. Additionally, the percentages of osteoblast surface over mineralized calluses and levels of the bone formation marker serum N-terminal propeptide of type I procollagen (P1NP) were comparable between CatK-I versus CON groups, while these bone formation parameters were decreased by ALN. Taken together, these results indicate that unlike ALN, CatK-I inhibits osteoclastic activity without changing bone formation, and the inhibition of CatK delayed but did not abrogate callus remodeling during bone repair.
组织蛋白酶 K 抑制剂(CatK-I)已被开发并确立用于恢复动物模型中骨质流失和绝经后骨质疏松症患者的骨量。我们研究了 CatK-I L-006235 对骨修复的影响,并将其与阿仑膦酸钠(ALN)进行了比较,后者在临床前模型中已知对骨折愈合有影响。在骨折后第 0 天开始给予载体(CON)、CatK-I 或 ALN 的野生型小鼠中进行股骨骨折,直至安乐死。放射学和 micro-CT 分析表明,CatK-I 在骨折后第 21 天增强了骨痂中的矿化,但程度低于 ALN。组织学分析显示,与 CON 相比,CatK-I 和 ALN 治疗组的骨痂中仍有未矿化和矿化软骨残留。CatK-I 增强了骨折骨痂中抗酒石酸酸性磷酸酶阳性(TRAP+)破骨细胞的数量,与 ALN 和 CON 治疗组相比。然而,与 CON 相比,CatK-I 和 ALN 组的骨痂内 TRAP+破骨细胞数量的血清 I 型胶原 C 末端肽(CTX)相对水平均显著降低。此外,CatK-I 组与 CON 组相比,矿化骨痂上的成骨细胞表面百分比和骨形成标志物血清 I 型前胶原 N 端前肽(P1NP)水平相当,而 ALN 降低了这些骨形成参数。总之,这些结果表明,与 ALN 不同,CatK-I 抑制破骨细胞活性而不改变骨形成,CatK 的抑制延迟但并未消除骨修复过程中的骨痂重塑。